Mycophenolate mofetil in islet cell transplant: Variable pharmacokinetics but good correlation between total and unbound concentrations

Journal of Clinical Pharmacology

Volumn 45, Issue 8, 2005, Pages 901-909

  Jacobson, Pamala A ^a   Green, Kathleen G ^a   Hering, Bernhard J ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Mycophenolate mofetil; Mycophenolic acid; Mycophenolic acid glucuronide; Pharmacokinetics

Indexed keywords

DACLIZUMAB; ETANERCEPT; GLUCURONIDE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID BETA D GLUCURONIDE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG MONITORING; FEMALE; GLUCURONIDATION; GRAFT FAILURE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LONGITUDINAL STUDY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; PANCREAS ISLET TRANSPLANTATION; TIME TO REACH MAXIMUM PLASMA CONCENTRATION;

ADULT; AREA UNDER CURVE; FEMALE; GLUCURONIDES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; LONGITUDINAL STUDIES; MYCOPHENOLIC ACID; PROTEIN BINDING; SIROLIMUS; TACROLIMUS; TREATMENT OUTCOME;

EID: 23044459877     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005278599     Document Type: Article

References (40)

1. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation. 1996;61:1029-1037.
2. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation. 1998;65:1450-1454.
3. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1995;60:225-232.
4. Lee CM, Markezich AJ, Scandling TD, Dalfoe DC, Alfrey EJ. Outcome in cadaveric renal transplant recipients treated with cyclosporine A and mycophenolate mofetil versus cyclosporine A and azathioprine. J Surg Res. 1998;76:131-136.
5. Oh JM, Wiland AM, Klassen DK, Weidle PJ, Bartlett ST. Comparison of azathioprine and mycophenolate mofetil for the prevention of acute rejection in recipients of pancreas transplantation. J Clin Pharmacol. 2001;41:861-869.
6. Merion RM, Henry ML, Melzer JS, Sollinger HW, Sutherland DE, Taylor RJ. Randomized, prospective trial of mycophenolate mofetil versus azathioprine for prevention of acute renal allograft rejection after simultaneous kidney-pancreas transplantation. Transplantation. 2000;70:105-111.
7. Odorico JS, Pirsch JD, Knechtle SJ, D'Alessandro AM, Sollinger HW. A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation. Transplantation. 1998;66:1751-1759.
8. Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc. 1996;28:925-929.
9. Picard N, Ratansavanh D, Premaud A, Le Meur Y, Marquet P. Identification of the UDP glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005;33:139-145.
10. Allison AC, Eugui EM. The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunopathol. 1993;14:353-380.
11. Cellcept [package insert]. Palo Alto, Calif: Roche Laboratories; 1998-2000.
12. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455.
13. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem. 1995;41:1011-1017.
14. Kaplan B, Gruber SA, Nallamathou R, Katz SM, Shaw LM. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation. 1998;65:1127-1129.
15. Meier-Kriesche HU, Shaw LM, Korecka M, Kaplan B. Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther Drug Monit. 2000;22:27-30.
16. Shaw LM, Pawinski T, Korecka M, Nawrocki A. Monitoring of mycophenolic acid in clinical transplantation. Ther Drug Monit. 2002;24:68-73.
17. DeNofrio D, Loh E, Kao A. et al. Mycophenolic acid concentrations are associated with cardiac allograft rejection. J Heart Lung Transplant. 2000;19:1071-1076.
18. Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002;62:1060-1067.
19. Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA. 2005;293:830-835.
20. Johnson AG, Rigby RJ, Taylor PJ, et al. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin Pharmacol Ther. 1999;66:492-500.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
22. Jones CE, Taylor PJ, Johnson AG. High-performance liquid chromatography determination of mycophenolic acid and its glucuronide metabolite in human plasma. J Chromatogr B Biomed Sci Appl. 1998;708:229-234.
23. Shipkova M, Strassburg CP, Braun F, et al. Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol. 2001;132:1027-1034.
24. Svensson JO, Brattstrom C, Sawe J. A simple HPLC method for simultaneous determination of mycophenolic acid and mycophenolic acid glucuronide in plasma. Ther Drug Monit. 1999;21:322-324.
25. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343:230-238.
26. Tsaroucha AK, Zucker K, Esquenazi V, de Faria L, Miller J, Tzakis AG. Levels of mycophenolic acid and its glucuronide derivative in the plasma of liver, small bowel and kidney transplant patients receiving tacrolimus and cellcept combination therapy. Transpl Immunol. 2000;8:143-146.
27. Zanker B, Sohr B, Eder M, Frohmann E, Land W. Comparison of MPA trough levels in patients with severe diabetes mellitus and from non-diabetics after transplantation. Transplant Proc. 1999;31:1167.
28. Shaw LM, Korecka M, Aradhye S, et al. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol. 2000;40:624-633.
29. Jain A, Venkataramanan R, Hamad IS, et al. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol. 2001;41:268-276.
30. Ensom MH, Partovi N, Decarie D, Dumont RJ, Fradet G, Levy RD. Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. Ther Drug Monit. 2002;24:310-314.
31. Ensom MH, Partovi N, Decarie D, Ignaszewski AP, Fradet GJ, Levy RD. Mycophenolate pharmacokinetics in early period following lung or heart transplantation. Ann Pharmacother. 2003;37:1761-1767.
32. Weber LT, Lamersdorf T, Shipkova M, et al. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit. 1999;21:498-506.
33. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation. 2000;69:1252-1260.
34. Filler G, Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit. 2000;22:169-173.
35. Shaw LM, Mick R, Nowak I, Korecka M, Brayman KL. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol. 1998;38:268-275.
36. Weber LT, Shipkova M, Lamersdorf T, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatrie and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol. 1998;9:1511-1520.
37. Atcheson BA, Taylor PJ, Kirkpatrick CM, et al. Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit. 2004;26:284-286.
38. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German Study Group on Mycophenolate Mofetil Therapy. J Am Soc Nephrol. 2002;13:759-768.
39. Mudge DW, Atcheson BA, Taylor PJ, Pillans PI, Johnson DW. Severe toxicity associated with a markedly elevated mycophenolic acid free fraction in a renal transplant recipient. Ther Drug Monit. 2004;26:453-455.
40. Shaw LM, Kaplan B, DeNofrio D, Korecka M, Brayman KL. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther Drug Monit. 2000;22:14-19.